W
William D. Fox
Researcher at Cedars-Sinai Medical Center
Publications - 10
Citations - 1994
William D. Fox is an academic researcher from Cedars-Sinai Medical Center. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 9, co-authored 10 publications receiving 1945 citations. Previous affiliations of William D. Fox include Memorial Sloan Kettering Cancer Center.
Papers
More filters
Journal ArticleDOI
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.
David B. Agus,Robert W. Akita,William D. Fox,Gail D. Lewis,Brian Higgins,Paul I. Pisacane,Julie A. Lofgren,Charles A. Tindell,Douglas P Evans,Krista Maiese,Howard I. Scher,Mark X. Sliwkowski +11 more
TL;DR: It is demonstrated that the in vitro and in vivo growth of several breast and prostate tumor models is inhibited by 2C4 treatment, which sterically hinders ErbB2's recruitment intoErbB ligand complexes.
Journal ArticleDOI
Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence.
David B. Agus,Carlos Cordon-Cardo,William D. Fox,Marija Drobnjak,Andrew Koff,David W. Golde,Howard I. Scher +6 more
TL;DR: The data suggest that androgen withdrawal results in a cell stress response, in which increased p53 protein produces a cell cycle arrest, without activation of p53-mediated apoptosis, and that the emergence of androgen independence is associated with a release fromcell cycle arrest.
Journal ArticleDOI
Dehydroascorbic acid, a blood–brain barrier transportable form of vitamin C, mediates potent cerebroprotection in experimental stroke
Judy Huang,David B. Agus,David B. Agus,Christopher J. Winfree,Szilard Kiss,William J. Mack,Ryan A McTaggart,Tanvir F. Choudhri,Louis J. Kim,J. Mocco,David J. Pinsky,William D. Fox,Robert J. Israel,Thomas A. Boyd,David W. Golde,E. Sander Connolly +15 more
TL;DR: As a naturally occurring interconvertible form of AA with BBB permeability, DHA represents a promising pharmacological therapy for stroke based on its effects in this model of cerebral ischemia.
Journal Article
Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1.
Lukas C. Amler,David B. Agus,Carrie LeDuc,M. Lisa Sapinoso,William D. Fox,Suzanne Kern,Dori Lee,Vivian Wang,Maurice Leysens,Brian Higgins,Jason Martin,William L. Gerald,Nicholas C. Dracopoli,Carlos Cordon-Cardo,Howard I. Scher,Garret M. Hampton +15 more
TL;DR: In this paper, changes in gene expression that occurred following androgen-deprivation of an androgendependent prostate tumor xenograft, CWR22, and the emergence of a androgen independent tumor was monitored using microarray analysis.
Journal Article
Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models.
David B. Agus,Howard I. Scher,Brian Higgins,William D. Fox,Glenn Heller,Melissa Fazzari,Carlos Cordon-Cardo,David W. Golde +7 more
TL;DR: In these prostate cancer model systems, Herceptin alone has clinical activity only in the androgen-dependent tumor and has at least an additive effect on growth, in combination with paclitaxel, in both androgens-dependent and androgen -independent tumors.